Abstract
At present, no guidelines on the appropriate withdrawal of ETN in JIA patients in clinical remission exist. The identification of predictors of clinical remission off medication (CROM) in these patients represents the initial step in their development.
Highlights
At present, no guidelines on the appropriate withdrawal of ETN in juvenile idiopathic arthritis (JIA) patients in clinical remission exist
The identification of predictors of clinical remission off medication (CROM) in these patients represents the initial step in their development
To evaluate the rate of CROM in JIA patients after ETN withdrawal; to identify predictors of CROM in these patients
Summary
No guidelines on the appropriate withdrawal of ETN in JIA patients in clinical remission exist. PReS-FINAL-2142: Predictors of persistent remission following etanercept (ETN) withdrawal in patients with juvenile idiopathic arthritis (JIA) F Perfetti1*, F Gesualdo2, V Messia1, A Insalaco1, C Bracaglia1, M Pardeo1, R Nicolai1, L Meli1, F De Benedetti1, S Magni Manzoni1 From 20th Pediatric Rheumatology European Society (PReS) Congress Ljubljana, Slovenia.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
